(RTTNews) - Retension Pharmaceuticals, Inc. (RTSN), a clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases, announced the pricing of its upsized initial public offering of 3.75 million shares at $12.00 per share. Retension Pharmaceuticals i
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。